
News


Quantitative assessment of retinovascular features on ultra-widefield angiography images showed significant improvements in leakage and ischemia following treatment with aflibercept in patients with diabetic macular edema and retinal vein occlusion.

Computerized testing of contrast sensitivity function using the Sentio Platform (Adaptive Sensory Technology) may better quantify the visual limitations of patients than traditional letter acuity after retinal detachment repair.














The metastatic prognosis does not increase when vitrectomy is performed at the time of brachytherapy.


RGX-314 gene therapy offers patients the potential for a lower treatment burden with one subretinal injection of a gene therapy delivering an anti-vascular endothelial growth factor protein.




Advances in optical coherence tomography (OCT) and OCT angiography (OCTA) may enable more objective and accurate diagnosis of ROP in the future.

Early results of a phase Ib/II study investigating light-activated AU-011 (Aura Biosciences) for treatment of small-medium choroidal melanoma show good safety and evidence of efficacy for this novel tumor-targeted therapy.

Management of patients with loss of light perception after open-globe injury has historically been to observe or enucleate the eye with the goal of reducing the risk of sympathetic ophthalmia. Existing data, however, support rethinking that paradigm and instead considering surgery for carefully selected patients who have a chance for recovering vision.

OCT angiography (OCTA) is a revolutionary new tool that adds value to clinical practice. It provides unique insights about retinal and choroidal vasculature compared with conventional OCT along with the advantages of conventional dye-based techniques, said Philip J. Rosenfeld, MD, PhD, at the 2017 Retina Subspecialty Day meeting.


Drs. David Brown, Rishi Singh, Rick Spaide, and Charles Wykoff talk about the top stories in medical and surgical retina from the previous year, and what they're looking forward to hearing on the podium from Retina Subspecialty Day 2017

Clinical trials are an indispensable ordeal that are the gold standard for assessing risks and benefits of treatments, said Frederick L. Ferris III, MD.
